Philippe Jean Bousquet

Summary

Country: France

Publications

  1. ncbi Provocation tests in diagnosing drug hypersensitivity
    Philippe Jean Bousquet
    Département Biostatistique, Epidemiologie Clinique, Santé Publique et Information Médicale, Hopital Caremeau, CHU de Nimes, 30029 Nimes Cedex 9, France
    Curr Pharm Des 14:2792-802. 2008
  2. ncbi Assessment of allergen sensitization in a general population-based survey (European Community Respiratory Health Survey I)
    Philippe Jean Bousquet
    National Heart and Lung Institute at Imperial College, London, UK
    Ann Epidemiol 20:797-803. 2010
  3. ncbi Immunotherapy: clinical trials--optimal trial and clinical outcomes
    Philippe Jean Bousquet
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Centre Hospitalier Universitaire, Montpellier, France
    Curr Opin Allergy Clin Immunol 7:561-6. 2007

Detail Information

Publications3

  1. ncbi Provocation tests in diagnosing drug hypersensitivity
    Philippe Jean Bousquet
    Département Biostatistique, Epidemiologie Clinique, Santé Publique et Information Médicale, Hopital Caremeau, CHU de Nimes, 30029 Nimes Cedex 9, France
    Curr Pharm Des 14:2792-802. 2008
    ....
  2. ncbi Assessment of allergen sensitization in a general population-based survey (European Community Respiratory Health Survey I)
    Philippe Jean Bousquet
    National Heart and Lung Institute at Imperial College, London, UK
    Ann Epidemiol 20:797-803. 2010
    ..Using the data collected during the ECRHS I (European Community Respiratory Health Survey), several assessments of skin prick tests and serum-specific IgE to identify mono- and polysensitized patients were compared...
  3. ncbi Immunotherapy: clinical trials--optimal trial and clinical outcomes
    Philippe Jean Bousquet
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Centre Hospitalier Universitaire, Montpellier, France
    Curr Opin Allergy Clin Immunol 7:561-6. 2007
    ..Although specific immunotherapy was introduced a century ago, very few trials meet the criteria for pivotal studies. The paper reviews the methods which should be used to investigate specific immunotherapy...